Heart Failure August 15, 2024
Rivus HU6 Shows Obesity-HFpEF Potential August 15, 2024
Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements - without the risk of muscle loss.
Artificial Intelligence August 12, 2024
Cardiology AI Clearances Growing, Diversifying August 12, 2024
The FDA updated its healthcare AI database last week, increasing its list of AI-enabled clearances to a whopping 950 medical devices, while highlighting some interesting trends in cardiovascular AI.
Heart Failure August 8, 2024
Bayer’s Kerendia Could Become First nsMRA Heart Failure Treatment August 8, 2024
Bayer’s nsMRA finerenone (Kerendia) might be on track to becoming a key heart failure treatment, after topline results from the FINEARTS-HF trial showed that finerenone significantly reduces cardiovascular death and HF events among patients with mildly reduced or preserved ejection fraction.
Heart Failure August 5, 2024
Tirzepatide Improves HFpEF Symptoms and Outcomes August 5, 2024
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.
Pharmaceuticals August 1, 2024
NewAmsterdam’s Obicetrapib Slashes HeFH LDL-C in First Phase 3 Trial August 1, 2024
Topline results are in from NewAmsterdam Pharma’s BROOKLYN study, showing that obicetrapib safely and effectively reduces LDL cholesterol in patients with heterozygous familial hypercholesterolemia who can’t be effectively treated by current cholesterol drugs.
Cardiology Business July 29, 2024
Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure July 29, 2024
Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
Surgeries & Interventions July 25, 2024
Magenta Medical Adds $105M, Targets MCS Disruption July 25, 2024
Israeli heart pump startup Magenta Medical wrapped up a $105M financing round to advance clinical programs supporting its Elevate left ventricular assist device, a percutaneous heart pump that Magenta believes could disrupt the mechanical circulatory support segment.
Patient Engagement July 22, 2024
The Psychological Impact of AFib Wearables July 22, 2024
AFib patients are increasingly using consumer wearable devices for symptom monitoring, but a new JAHA study suggests that these devices' often-publicized healthcare benefits are offset by their negative impacts on patient anxiety and healthcare overuse.
Pharmaceuticals July 18, 2024
Lexeo LX2006 Shows Promise for Friedreich’s Ataxia Cardiomyopathy July 18, 2024
Lexeo Therapeutics gave the 5,000 Americans with Friedreich’s ataxia cardiomyopathy reason for optimism, publishing early results that suggest its LX2006 gene therapy could be able to treat FA cardiomyopathy.
Surgeries & Interventions July 15, 2024
Baylor St. Luke’s Settles Concurrent Cardiac Surgery Case July 15, 2024
Cardiac surgeon compensation is generally a numbers game - the more procedures you do, the more you make. However, a Medicare fraud settlement featuring some of Houston’s most prominent institutions and cardiac surgeons reveals the pitfalls of this incentive structure.
Population Health July 11, 2024
Nearly Half of American Counties Don’t Have Cardiologists July 11, 2024
A new JACC study found that 46.3% of U.S. counties don’t have a single cardiologist, meaning that the 22M people who live in these "cardiology desert" countries have to drive an average of 90 miles round trip to see their cardiologist.
Structural Heart July 8, 2024
Older Patients and Asymptomatic Valvular Heart Disease July 8, 2024
A new study out of the UK found that over a quarter of people aged 60+ have asymptomatic valvular heart disease, and revealed that prevalence increases as patients age -- potentially providing new reasons to screen older patients for VHD.
Cardiology July 1, 2024
Cardiology in H1 2024 July 1, 2024
The first half of 2024 is now a wrap, and it was another big one in cardiology. Here are some of Cardiac Wire’s top six storylines from the last six months, plus some things to keep in mind as we head into 2024’s second half.
Surgeries & Interventions June 27, 2024
Shockwave Therapy’s Ischemic Heart Failure Potential June 27, 2024
New research out of Austria suggests that cardiac shockwave therapy could help address ischemic heart failure patients’ myocardial regeneration challenges, allowing meaningful LVEF and quality of life improvements, and potentially better outcomes.
Artificial Intelligence June 24, 2024
New Echo AI Model Could Streamline Mitral Regurgitation Diagnosis June 24, 2024
Columbia and Cornell researchers developed an echo AI model that could improve the difficult task of mitral regurgitation diagnosis, and might even represent an AI-driven step towards enhancing all valvular regurgitation assessments.
Pharmaceuticals June 20, 2024
Marea Therapeutics’ Cardiometabolic Mission June 20, 2024
Marea Therapeutics emerged this week, announcing $190M in Series A/B funding and a mission to develop "a new generation of medicines for cardiometabolic diseases" - starting with their drug candidate targeting remnant cholesterol.
Cardiology Practices June 17, 2024
The Rise of Private Equity Cardiology Practice Acquisitions June 17, 2024
New research in JAMA highlighted the rapid growth of private equity-backed cardiology practice acquisitions, while revealing some interesting geographic factors driving this growth.
Preventive Cardiology June 13, 2024
New Calculations Could Slash Statin-Eligible Population June 13, 2024
A JAMA paper suggests that if the CVD guidelines adopt the AHA’s new PREVENT cardiovascular risk equations, it might slash the US’s eligible preventive statin user population by nearly 40%.
Structural Heart June 10, 2024
Edwards’ Strong Five-Year Small Annulus TAVR Outcomes June 10, 2024
Edwards and Medtronic’s fight for TAVR supremacy took an interesting turn last week, after Edwards showed that its SAPIEN 3 valve has similar five-year outcomes among patients with both small and large aortic annulus, regardless of their mean gradients and rates of prothesis-patient mismatch.
